Lp(a)-Lowering Treatments in 2026: What’s Available Now and What the Latest Trials Show

Lipoprotein(a), or Lp(a), has become one of the most closely watched targets in cardiovascular medicine. High Lp(a) is largely inherited, is associated with atherosclerotic cardiovascular disease and calcific aortic valve disease, and usually changes very little with diet, exercise, or weight loss. That combination has created strong interest in treatments capable of lowering Lp(a) directly.

The treatment picture in 2026 is more complicated than headlines about dramatic Lp(a) reductions might suggest. Several investigational drugs can lower Lp(a) by 80%, 90%, or even more in clinical trials, but lowering a laboratory measurement is not enough. What ultimately matters is whether treatment prevents heart attacks, strokes, cardiovascular deaths, and other important outcomes without creating unacceptable risks.

That distinction became particularly important on September 4, 2026, when Novartis announced that the phase 3 Lp(a)HORIZON trial of pelacarsen successfully lowered Lp(a) but did not meet its primary cardiovascular-outcomes endpoint. Meanwhile, other major phase 3 programs involving olpasiran, lepodisiran, and the oral drug muvalaplin are continuing.

As of September 24, 2026, there is still no approved medication specifically indicated to lower Lp(a) and proven through a dedicated outcomes trial to reduce cardiovascular events by targeting Lp(a). Existing treatments can nevertheless help manage the broader cardiovascular risk associated with an elevated result.

Why lowering Lp(a) has proved harder than simply lowering the number

There is strong genetic and observational evidence connecting elevated Lp(a) with atherosclerotic cardiovascular disease. Those findings make Lp(a) an attractive therapeutic target, but they do not automatically prove that lowering Lp(a) with any particular drug will reduce clinical events.

A successful treatment must clear several hurdles. It has to reduce Lp(a) by enough, maintain that reduction for long enough, reach patients whose risk is actually driven enough by Lp(a) to show a benefit, and do so safely on top of modern cardiovascular therapies.

Today’s high-risk patients may already be receiving statins, ezetimibe, PCSK9-directed treatments, antihypertensive therapy, antiplatelet drugs, diabetes medications, and other preventive care. An experimental Lp(a) drug therefore has to demonstrate additional benefit beyond already effective treatment.

This is why phase 2 results showing a 90% reduction in Lp(a) are scientifically exciting but cannot answer the most important patient question: Will taking this drug actually make me less likely to have a heart attack or stroke?

What can doctors use for high Lp(a) right now?

There is an important distinction between treatments available to people who have high Lp(a) and treatments approved specifically to target Lp(a).

The first category already contains useful options. The second remains very limited.

Statins reduce risk without lowering Lp(a)

Statins remain a foundation of treatment for many people at increased cardiovascular risk because they reduce LDL cholesterol, ApoB-containing particles, and cardiovascular events.

They do not meaningfully lower Lp(a). The 2026 ACC/AHA dyslipidemia guideline notes that statins may even modestly increase Lp(a) in some patients, but specifically states that this small change is not a reason to stop statin therapy because the cardiovascular benefits of appropriate statin treatment are well established.

For someone with high Lp(a), therefore, a statin can still be highly valuable even when the Lp(a) measurement barely changes.

Ezetimibe and bempedoic acid primarily address LDL-related risk

Other lipid-lowering drugs, including ezetimibe and bempedoic acid, can be used when additional LDL-C reduction is appropriate.

Neither is considered a potent Lp(a)-lowering treatment. Their role in someone with elevated Lp(a) is mainly to reduce other modifiable atherogenic lipoproteins rather than directly correcting the inherited Lp(a) concentration.

PCSK9 monoclonal antibodies modestly lower Lp(a)

PCSK9-directed therapy occupies an interesting middle ground.

The 2026 ACC/AHA guideline reports that PCSK9-directed treatments can reduce Lp(a) by approximately 15% to 30%, while producing much larger reductions in LDL-C and ApoB. For people with established atherosclerotic cardiovascular disease, elevated Lp(a), and LDL-C or non-HDL-C still above treatment goals despite maximally tolerated statin therapy, the guideline recommends adding a PCSK9 monoclonal antibody with demonstrated cardiovascular benefit when appropriate.

However, PCSK9 monoclonal antibodies should not be described as dedicated Lp(a) treatments. Their cardiovascular benefit occurs in the setting of profound LDL-related lowering, and existing trials do not prove that their modest effect on Lp(a) independently accounts for the reduction in cardiovascular events.

Lipoprotein apheresis is available, but only for selected patients

Lipoprotein apheresis is currently the most direct clinically available way to remove substantial amounts of circulating Lp(a).

During apheresis, blood passes through specialized equipment that removes ApoB-containing lipoproteins before the blood is returned to the patient. Both LDL and Lp(a) can fall substantially after a session, but levels begin rising again afterward, so treatment generally has to be repeated.

This is not routine therapy for everyone whose Lp(a) exceeds 50 mg/dL.

The 2026 ACC/AHA guideline describes a narrow U.S. FDA-approved indication involving people with clinically diagnosed heterozygous familial hypercholesterolemia, Lp(a) of at least 60 mg/dL or approximately 130 nmol/L, and documented coronary or peripheral artery disease.

Apheresis is therefore mainly a specialist treatment for selected very-high-risk patients rather than a practical population-wide solution to elevated Lp(a).

Why niacin is not the answer despite lowering Lp(a)

Niacin is frequently mentioned in discussions about Lp(a) because pharmacologic doses can lower the concentration.

That does not mean it should be taken for that purpose.

Modern clinical trials of niacin added to contemporary cardiovascular therapy failed to establish the expected additional reduction in cardiovascular events despite improving several lipid measurements, while adverse effects remained an important concern.

Current lipid guidance therefore does not recommend niacin simply to lower an elevated Lp(a) result.

Niacin illustrates one of the central lessons of Lp(a) research: a better-looking laboratory result is not enough to establish a useful treatment.

Pelacarsen: the first major Lp(a) outcomes test did not meet its primary endpoint

Pelacarsen was one of the most anticipated drugs in cardiovascular medicine because it was the first targeted Lp(a)-lowering therapy to reach a large phase 3 cardiovascular-outcomes trial.

Pelacarsen is an antisense oligonucleotide. Rather than physically removing Lp(a) from the bloodstream, it targets the messenger RNA involved in production of apolipoprotein(a) in the liver. Reducing apo(a) production reduces formation of new Lp(a) particles.

The phase 3 Lp(a)HORIZON trial enrolled 8,323 people with established cardiovascular disease and elevated Lp(a). Participants were already receiving guideline-directed care, including lipid-lowering and blood-pressure treatment.

On September 4, 2026, Novartis announced the topline result: pelacarsen lowered Lp(a), but it did not significantly reduce the study’s primary composite endpoint compared with placebo. That endpoint included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and urgent coronary revascularization requiring hospitalization.

That result is important because Lp(a)HORIZON moved the field beyond the question of whether a drug can lower Lp(a). Pelacarsen did that. The harder question was whether the reduction translated into fewer major cardiovascular events, and the primary outcome did not demonstrate that benefit.

What the pelacarsen result does—and does not—prove

The finding means pelacarsen failed to meet the primary efficacy endpoint in this particular trial. It should therefore prevent claims that targeted Lp(a) lowering has already been proven to reduce cardiovascular events.

It does not, by itself, prove that Lp(a) is unimportant or that every other Lp(a)-lowering drug will fail.

Different agents use different mechanisms, produce different degrees and durations of Lp(a) reduction, and are being studied in different patient populations.

There is also an important limitation as of September 24, 2026: the Novartis announcement reported topline results. Complete peer-reviewed trial data have not yet been published in the source reviewed for this article. Detailed information about subgroups, achieved Lp(a) concentrations, secondary endpoints, and other analyses therefore should not be assumed before the complete results become available.

Olpasiran: very large reductions, with outcomes trials underway

Olpasiran is a small interfering RNA, or siRNA, therapy designed to suppress production of apolipoprotein(a) in the liver.

In the phase 2 OCEAN(a)-DOSE study, 281 people with established atherosclerotic cardiovascular disease and Lp(a) above 150 nmol/L received various doses of olpasiran or placebo.

Higher doses produced placebo-adjusted reductions in Lp(a) exceeding 95% at week 36. Injection-site reactions were the most common treatment-related adverse events, and the overall incidence of adverse events was similar across treatment groups.

Those numbers established that olpasiran can suppress Lp(a) dramatically. But the investigators explicitly noted that larger and longer trials were required to determine whether this translates into fewer cardiovascular events.

As of 2026, that question is being tested in phase 3.

Amgen reports that OCEAN(a)-Outcomes, a secondary-prevention cardiovascular-outcomes study in people with established atherosclerotic cardiovascular disease and elevated Lp(a), remains ongoing. The company has also initiated OCEAN(a)-PreEvent, which is studying people with elevated Lp(a) who are at high risk for a first major cardiovascular event.

Until those trials report clinical outcomes, olpasiran remains investigational.

Lepodisiran: an siRNA designed for long-lasting suppression

Lepodisiran is another siRNA therapy targeting Lp(a) production, with a particular focus on creating a prolonged effect from infrequent injections.

The phase 2 ALPACA trial included 320 participants whose median baseline Lp(a) concentration was approximately 254 nmol/L.

At the highest studied dose, lepodisiran produced a placebo-adjusted time-averaged Lp(a) reduction of 93.9% between days 60 and 180. Participants who received 400 mg at baseline and again at day 180 had a placebo-adjusted time-averaged reduction of 94.8% from day 30 through day 360. Dose-dependent injection-site reactions were generally mild, and investigators did not judge any serious adverse events to be treatment related.

Again, that is evidence of powerful biomarker lowering—not yet evidence of fewer heart attacks or strokes.

The phase 3 ACCLAIM-Lp(a) study is testing whether lepodisiran can reduce major cardiovascular events in adults with elevated Lp(a) who either have established atherosclerotic cardiovascular disease or are considered at risk for a first cardiovascular event. Lilly’s current trial information identifies the program as phase 3.

A separate phase 3 imaging study, ACCLAIM-CTA, began in 2026 and is examining whether lepodisiran affects coronary plaque measured with CT angiography.

Muvalaplin: a different approach because it is an oral small molecule

Most advanced targeted Lp(a) drugs have been injectable RNA-based therapies.

Muvalaplin is different.

It is an oral small molecule designed to inhibit formation of Lp(a) rather than suppressing LPA messenger RNA with an antisense or siRNA approach.

In the phase 2 KRAKEN trial, 233 participants with Lp(a) of at least 175 nmol/L and cardiovascular disease, diabetes, or familial hypercholesterolemia were assigned to oral muvalaplin or placebo.

Depending on dose and the laboratory assay used, placebo-adjusted Lp(a) reductions reached 85.8% with an intact-particle assay and approximately 70% with an apo(a)-based assay. The trial did not identify major safety or tolerability concerns, but it was not designed to establish a reduction in cardiovascular events.

Muvalaplin has now entered the phase 3 MOVE-Lp(a) cardiovascular-outcomes program. Lilly reports that the trial is enrolling adults with elevated Lp(a) and atherosclerotic cardiovascular disease, with a planned enrollment of more than 10,000 participants.

Its oral formulation could eventually distinguish it from injectable therapies if efficacy and safety are confirmed, but that possibility remains investigational rather than established clinical practice.

How the leading treatments compare in 2026

Treatment	Approach	What we know about Lp(a) lowering	Cardiovascular-outcomes status in September 2026	Available specifically for high Lp(a)?
Pelacarsen	Antisense oligonucleotide injection	Lowers Lp(a)	Phase 3 Lp(a)HORIZON did not meet its primary cardiovascular endpoint	No
Olpasiran	siRNA injection	Higher phase 2 doses lowered Lp(a) by more than 95%	OCEAN(a)-Outcomes ongoing; OCEAN(a)-PreEvent underway	No
Lepodisiran	Long-duration siRNA injection	About 94% placebo-adjusted reduction at the highest phase 2 regimen during the primary assessment period	ACCLAIM-Lp(a) phase 3 outcomes trial underway	No
Muvalaplin	Oral small molecule	Up to 85.8% in phase 2 using an intact Lp(a) assay	MOVE-Lp(a) phase 3 outcomes trial enrolling	No
PCSK9 monoclonal antibodies	Injectable PCSK9 inhibition	Approximately 15%–30% Lp(a) reduction	Proven cardiovascular benefit in appropriate populations, but not specifically as Lp(a)-targeted therapy	No
Lipoprotein apheresis	Blood-filtration procedure	Substantially lowers circulating Lp(a) temporarily	Used for selected very-high-risk patients under narrow indications	Available only for qualifying patients

The percentages should not be used to rank these drugs as treatments. They come from different trials, doses, populations, durations, and laboratory methods, and the investigational agents have not yet demonstrated equivalent clinical outcomes.

Why a 90% Lp(a) reduction does not automatically make one drug “better”

It is tempting to compare the drugs simply by looking at percentage reductions.

That can be misleading for several reasons.

First, Lp(a) assays and trial designs can differ. The muvalaplin trial, for example, demonstrated that the measured percentage reduction depended partly on whether investigators used an intact-particle assay or a traditional apo(a)-based assay.

Second, treatment frequency and duration matter. A medication producing a large reduction shortly after dosing may not have the same biological effect as one maintaining sustained suppression over months or years.

Third, cardiovascular benefit may depend on absolute Lp(a) reduction, baseline Lp(a), underlying cardiovascular risk, duration of treatment, and other factors that cannot be determined simply from the largest percentage printed in a phase 2 trial.

Most importantly, patients take cardiovascular medication to reduce illness and death—not merely to obtain a lower laboratory number.

For that reason, a drug that lowers Lp(a) by 95% but fails to prevent cardiovascular events would not automatically be more useful than an intervention producing a smaller biochemical change but a proven reduction in heart attacks and strokes.

What does pelacarsen’s result mean for the other phase 3 trials?

The most responsible interpretation is that the field now needs the remaining trials more, not less.

Pelacarsen provided the first major randomized test of whether a targeted Lp(a)-lowering strategy could add cardiovascular benefit to contemporary care, and its primary endpoint was negative.

Olpasiran, lepodisiran, and muvalaplin cannot be assumed to succeed because they produce larger percentage reductions in earlier studies. Nor should they be assumed to fail simply because pelacarsen did.

Their phase 3 trials need to answer the question directly.

Until then, claims that a specific investigational drug “prevents Lp(a) heart disease” or that an 80%–95% laboratory reduction necessarily translates into an equivalent reduction in cardiovascular risk go beyond the evidence.

Are any of these drugs available through a doctor now?

The investigational drugs discussed above are not routine prescription treatments for high Lp(a).

People may encounter clinical trials studying these therapies, but enrolling in a trial is different from receiving an approved treatment. Clinical trials use defined inclusion and exclusion criteria, participants may receive placebo, and investigational drugs can have benefits and risks that are not yet completely understood.

For people who currently have elevated Lp(a), the practical emphasis remains on reducing the modifiable cardiovascular risk surrounding it.

That can include appropriate LDL-C and ApoB lowering, blood-pressure control, diabetes management, avoiding tobacco, physical activity, a heart-supportive dietary pattern, and medication when clinically indicated.

For a broader discussion of those steps, see our guide to what you can do about high Lp(a).

What should people with high Lp(a) do while waiting for the trials?

Waiting for a targeted drug should not mean waiting to address cardiovascular risk.

The 2026 ACC/AHA guideline recommends early, optimal management of modifiable risk factors for anyone with elevated Lp(a), defined in the guideline as at least 125 nmol/L or 50 mg/dL. Elevated Lp(a) can also favor more intensive lipid-lowering treatment according to a person’s overall cardiovascular risk.

That means the most immediately useful questions are often not, “How do I get my Lp(a) down to zero?” but rather:

What is my LDL-C? Is my ApoB or non-HDL cholesterol still high? Is my blood pressure controlled? Do I smoke? Do I have diabetes or kidney disease? Have I already developed atherosclerotic cardiovascular disease? Does my family need Lp(a) testing?

Those questions involve risks that can be acted on now.

Anyone considering medication changes because of an Lp(a) result should discuss them with the clinician managing their cardiovascular care rather than stopping established therapy or starting unproven supplements independently.

Where Lp(a) treatment stands at the end of 2026

Lp(a) research has reached a pivotal stage.

Scientists can now lower the biomarker far more effectively than was possible a decade ago. Olpasiran and lepodisiran have produced reductions around or above 90% in phase 2 testing at higher regimens, while the oral agent muvalaplin has also demonstrated substantial reductions.

But September 2026 also provided an important reminder about the difference between biological plausibility, biomarker success, and clinical benefit. Pelacarsen lowered Lp(a), yet Lp(a)HORIZON did not meet its primary cardiovascular endpoint.

The remaining phase 3 programs are therefore not formalities. Their cardiovascular-outcomes results are the evidence needed to determine whether large, sustained reductions in Lp(a) can meaningfully prevent cardiovascular events—and which patients, treatments, and degrees of lowering matter most.

For now, high Lp(a) is actionable primarily because it identifies people whose overall cardiovascular risk deserves careful attention. Targeted treatment may eventually change that picture, but the evidence is still being written.

References

1. Blumenthal RS, Morris PB, Gaudino M, et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.” Circulation and Journal of the American College of Cardiology, 2026.
2. Novartis. “Novartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients With Elevated Lp(a) and Established Cardiovascular Disease.” September 4, 2026.
3. O’Donoghue ML, Rosenson RS, Gencer B, et al. “Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.” New England Journal of Medicine, 2022;387:1855–1864.
4. Nissen SE, Ni W, Shen X, et al. “Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).” New England Journal of Medicine, 2025;392:1673–1683.
5. Nicholls SJ, Ni W, Rhodes GM, et al. “Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.” JAMA, 2025;333:222–231.
6. Amgen. “Second Quarter 2026 Financial Results.” Pipeline update describing the ongoing OCEAN(a) phase 3 olpasiran program, 2026.